GPP
PRTK

Great Point Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Great Point Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-539,571
Closed -$10.4M – 45
2017
Q1 		$10.4M Buy
+539,571
New +$8.5M 2.06% 18
2016
Q3 		– Sell
-29,266
Closed -$407K – 51
2016
Q2 		$407K Sell
29,266
-276,193
-90% -$4.07M 0.12% 33
2016
Q1 		$4.63M Sell
305,459
-50,000
-14% -$765K 1.66% 20
2015
Q4 		$6.74M Sell
355,459
-98,419
-22% -$1.88M 2.83% 12
2015
Q3 		$8.62M Buy
453,878
+38,540
+9% +$960K 3.41% 11
2015
Q2 		$10.7M Buy
+415,338
New +$11.8M 4.17% 7

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Great Point Partners's PRTK Position: Q2 2017 in Review

Great Point Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2017, closing a stake of 539,571 shares — an estimated $10.4M sold.

Great Point Partners first reported a position in PRTK in Q2 2015 and held it in 6 quarters. The position peaked at $10.7M in Q2 2015. 119 funds tracked by Wall St. Rank hold PRTK as of Q2 2017.

  • Great Point Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Great Point Partners sold 539,571 Paratek Pharmaceuticals, Inc. shares in Q2 2017, an estimated $10.4M.
  • Great Point Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 6 quarters.
  • Great Point Partners's Paratek Pharmaceuticals, Inc. position peaked at $10.7M in Q2 2015.
  • 119 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2017.

Based on Great Point Partners's 13F filing for Q2 2017, filed 14 Aug 2017.